David Bishop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Bishop has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Emily Blyth
Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia
8 shared publications K. Micklethwaite
7 shared publicationsD. Gottlieb
6 shared publications- David Jonathan Gottlieb
Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia
6 shared publications A. Dolnikov
4 shared publicationsKenneth Micklethwaite
Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia
4 shared publications
Latest Publications
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7018-7022
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7018-7022
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL
- 18 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (25) , 3124-3128
Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients
Human herpesvirus 6 reactivation in chimeric antigen receptor T-cell recipients is reported to be rare. Our patient cohort (n = 119) experienced a sevenfold higher incidence of viremia than a previous study and 2 cases of encephalitis. Further studies are needed to determine risk factors for infection.
- 18 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (25) , 3124-3128
Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients
Human herpesvirus 6 reactivation in chimeric antigen receptor T-cell recipients is reported to be rare. Our patient cohort (n = 119) experienced a sevenfold higher incidence of viremia than a previous study and 2 cases of encephalitis. Further studies are needed to determine risk factors for infection.
- Open Access
- 27 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR+ T cells, such as product composition, patients’ lymphodepletion, and immune reconstitution, are not well understood. To shed light on this issue, here we conduct a single-cell multi-omics analysis of transcriptional, clonal, and phenotypic profiles from pre- to 1-month post-infusion of CAR+ and CAR− T cells from patients from a CARTELL study (ACTRN12617001579381) who received a donor-derived 4-1BB CAR product targeting CD19. Following infusion, CAR+ T cells and CAR− T cells shows similar differentiation profiles with clonally expanded populations across heterogeneous phenotypes, demonstrating clonal lineages and phenotypic plasticity. We validate these findings in 31 patients with large B cell lymphoma treated with CD19 CAR T therapy. For these patients, we identify using longitudinal mass-cytometry data an association between NK-like subsets and clinical outcomes at 6 months with both CAR+ and CAR− T cells. These results suggest that non-CAR-derived signals can provide information about patients’ immune recovery and be used as correlate of clinically relevant parameters.
- 27 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Open AccessCAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR+ T cells, such as product composition, patients’ lymphodepletion, and immune reconstitution, are not well understood. To shed light on this issue, here we conduct a single-cell multi-omics analysis of transcriptional, clonal, and phenotypic profiles from pre- to 1-month post-infusion of CAR+ and CAR− T cells from patients from a CARTELL study (ACTRN12617001579381) who received a donor-derived 4-1BB CAR product targeting CD19. Following infusion, CAR+ T cells and CAR− T cells shows similar differentiation profiles with clonally expanded populations across heterogeneous phenotypes, demonstrating clonal lineages and phenotypic plasticity. We validate these findings in 31 patients with large B cell lymphoma treated with CD19 CAR T therapy. For these patients, we identify using longitudinal mass-cytometry data an association between NK-like subsets and clinical outcomes at 6 months with both CAR+ and CAR− T cells. These results suggest that non-CAR-derived signals can provide information about patients’ immune recovery and be used as correlate of clinically relevant parameters.
- Open Access
- 14 April 2022
- Published by Springer Nature in Research Square
CAR+ and CAR- T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusion
Chimeric antigen receptor (CAR) T cells have demonstrable efficacy in treating B-cell malignancies. Factors such as product composition, lymphodepletion and immune reconstitution are known to influence functional persistence of CAR+ T cells. However, little is known about the determinants of differentiation and phenotypic plasticity of CAR+ T and immune cells early post-infusion. We report single cell multi-omics analysis of molecular, clonal, and phenotypic profiles of CAR+ T and other immune cells circulating in patients receiving donor-derived products. We used these data to reconstruct a differentiation trajectory, which explained the observed phenotypic plasticity and identified cell fate of CAR+ and CAR- T cells. Following lympho-depletion, endogenous CAR- CD8+ and 𝛾ẟ T cells, clonally expand, and differentiate across heterogenous phenotypes, from a dominant resting or proliferating state into precursor of exhausted T cells, and notably into a terminal NK-like phenotype. In parallel, following infusion, CAR+ T cells undergo a similar differentiation trajectory, showing increased proliferation, metabolic activity and exhaustion when compared to circulating CAR- T cells. The subset of NK-like CAR+ T cells was associated with increasing levels of circulating proinflammatory cytokines, including innate-like IL-12 and IL-18. These results demonstrate that differentiation and phenotype of CAR+ T cells are determined by non-CAR induced signals that are shared with endogenous T cells, and condition the patients’ immune-recovery.
- 14 April 2022
- Published by Springer Nature in Research Square
Open AccessCAR+ and CAR- T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusion
Chimeric antigen receptor (CAR) T cells have demonstrable efficacy in treating B-cell malignancies. Factors such as product composition, lymphodepletion and immune reconstitution are known to influence functional persistence of CAR+ T cells. However, little is known about the determinants of differentiation and phenotypic plasticity of CAR+ T and immune cells early post-infusion. We report single cell multi-omics analysis of molecular, clonal, and phenotypic profiles of CAR+ T and other immune cells circulating in patients receiving donor-derived products. We used these data to reconstruct a differentiation trajectory, which explained the observed phenotypic plasticity and identified cell fate of CAR+ and CAR- T cells. Following lympho-depletion, endogenous CAR- CD8+ and 𝛾ẟ T cells, clonally expand, and differentiate across heterogenous phenotypes, from a dominant resting or proliferating state into precursor of exhausted T cells, and notably into a terminal NK-like phenotype. In parallel, following infusion, CAR+ T cells undergo a similar differentiation trajectory, showing increased proliferation, metabolic activity and exhaustion when compared to circulating CAR- T cells. The subset of NK-like CAR+ T cells was associated with increasing levels of circulating proinflammatory cytokines, including innate-like IL-12 and IL-18. These results demonstrate that differentiation and phenotype of CAR+ T cells are determined by non-CAR induced signals that are shared with endogenous T cells, and condition the patients’ immune-recovery.
- Top Cited Papers
- 21 October 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (16) , 1504-1509
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells
Key Points. Matched sibling donor-derived piggyBac CAR T-cells showed 100% CR rate against CD19+ malignancy relapsed/refractory following allo-HSCT.Two cases of
- 21 October 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (16) , 1504-1509
Top Cited PapersDevelopment of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells
Key Points. Matched sibling donor-derived piggyBac CAR T-cells showed 100% CR rate against CD19+ malignancy relapsed/refractory following allo-HSCT.Two cases of
- Open Access
- 1 June 2020
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 359-368
CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
- 1 June 2020
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 359-368
Open AccessCAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
- 1 May 2019
- Published by Elsevier in Cytotherapy
- Vol. 21 (5) , S9
Matched sibling donor-derived piggybac CAR19 T cells induce remission of relapsed/refractory CD19+ malignancy following haematopoietic stem cell transplant
- 1 May 2019
- Published by Elsevier in Cytotherapy
- Vol. 21 (5) , S9
Matched sibling donor-derived piggybac CAR19 T cells induce remission of relapsed/refractory CD19+ malignancy following haematopoietic stem cell transplant
- Open Access
- 1 August 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (8) , 1883-1895
PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
- 1 August 2018
- Published by Elsevier in Molecular Therapy
- Vol. 26 (8) , 1883-1895
Open AccessPiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
- 1 May 2018
- Published by Elsevier in Cytotherapy
- Vol. 20 (5) , S8
Factors promoting CD19-negative relapses following CAR19T cell therapy
- 1 May 2018
- Published by Elsevier in Cytotherapy
- Vol. 20 (5) , S8
Factors promoting CD19-negative relapses following CAR19T cell therapy